Damian C. Crowther

AstraZeneca (United Kingdom) — United Kingdom

Medicine · Health Sciences

41h-index5.1kcitations97works20.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(38), Cholinesterase and Neurodegenerative Diseases(21), Protease and Inhibitor Mechanisms(12), Endoplasmic Reticulum Stress and Disease(12), Genetics, Aging, and Longevity in Model Organisms(11)

Publications97 total

A molecular stabiliser of an inhibitory eIF2B-eIF2(αP) complex activates the Integrated Stress Response
2025· 1 citedOpen Access
The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence
Alzheimer s & Dementia·2024· 19 citedOpen Access
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Nature Communications·2024· 42 citedOpen Access
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease
2022Open Access
Sensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF
Scientific Reports·2021· 26 citedOpen Access
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
2021Open Access
Loss of neuronal Miro1 disrupts mitophagy and induces hyperactivation of the integrated stress response
The EMBO Journal·2021· 65 citedOpen Access
Sensitization of the UPR by Loss of PPP1R15A Promotes Fibrosis and Senescence in IPF
Research Square (Research Square)·2021Open Access
Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer's disease.
Apollo (University of Cambridge)·2021Open Access
Soluble amyloid beta-containing aggregates are present throughout the brain at early stages of Alzheimer’s disease
Brain Communications·2021· 71 citedOpen Access
Using a Drosophila model of Alzheimer's disease
2020· 3 cited
Utilizing microphysiological systems and induced pluripotent stem cells for disease modeling: a case study for blood brain barrier research in a pharmaceutical setting
Advanced Drug Delivery Reviews·2018· 29 cited
Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a Drosophila model of Alzheimer's disease
Journal of Biological Chemistry·2018· 35 citedOpen Access
Central and peripheral circadian clocks and their role in Alzheimer's disease
Disease Models & Mechanisms·2017· 59 citedOpen Access
<scp>TREM</scp> 2 shedding by cleavage at the H157‐S158 bond is accelerated for the Alzheimer's disease‐associated H157Y variant
EMBO Molecular Medicine·2017· 213 citedOpen Access
CCT complex restricts neuropathogenic protein aggregation via autophagy
Nature Communications·2016· 137 citedOpen Access
Flyglow: Single-fly observations of simultaneous molecular and behavioural circadian oscillations in controls and an Alzheimer’s model
Scientific Reports·2016· 5 citedOpen Access
Progressive myoclonus epilepsy associated with neuroserpin inclusion bodies (neuroserpinosis)
Epileptic Disorders·2016· 23 cited
Expression of the alternative oxidase mitigates beta-amyloid production and toxicity in model systems
Free Radical Biology and Medicine·2016· 45 citedOpen Access
Metabolic changes may precede proteostatic dysfunction in a  Drosophila model of amyloid beta peptide toxicity
Neurobiology of Aging·2016· 14 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

David A. Lomas(14), David A. Lomas(13), Stefan J. Marciniak(11), Elena Miranda(9), Christopher M. Dobson(9), Didier Belorgey(8), Leila M. Luheshi(7), Michele Vendruscolo(6), Kerri J. Kinghorn(5), Aileen M. Moloney(5), Sally E. Thomas(5), Gian Gaetano Tartaglia(5), Juan L. Barja(5), Benoit D. Roussel(4), David A. Lomas(4), Giorgio Favrin(4), Ann‐Christin Brorsson(4), Jan Johansson(4), Lynda K. Sharp(4), Elke Malzer(4)